Proficio Capital Partners LLC Acquires New Holdings in Cencora, Inc. (NYSE:COR)

Proficio Capital Partners LLC purchased a new position in Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 142,139 shares of the company's stock, valued at approximately $31,936,000. Proficio Capital Partners LLC owned approximately 0.07% of Cencora at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Prime Capital Investment Advisors LLC boosted its stake in Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock worth $848,000 after buying an additional 46 shares in the last quarter. Shepherd Financial Partners LLC lifted its holdings in shares of Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after acquiring an additional 46 shares during the period. WASHINGTON TRUST Co lifted its holdings in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the period. JFS Wealth Advisors LLC lifted its holdings in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. Finally, Trilogy Capital Inc. lifted its holdings in shares of Cencora by 5.1% during the fourth quarter. Trilogy Capital Inc. now owns 1,038 shares of the company's stock valued at $233,000 after acquiring an additional 50 shares during the period. Institutional investors own 97.52% of the company's stock.

Remove Ads

Cencora Trading Up 1.2 %

NYSE:COR traded up $3.06 on Tuesday, hitting $264.02. 1,721,850 shares of the stock were exchanged, compared to its average volume of 1,353,110. The stock has a market capitalization of $51.20 billion, a price-to-earnings ratio of 37.56, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $265.36. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company's 50-day moving average price is $248.23 and its 200 day moving average price is $239.31.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.83%. Cencora's payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company's stock, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on COR shares. JPMorgan Chase & Co. lifted their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company lifted their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target for the company. Finally, Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average target price of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.